Compare AbCellera Biologics Inc (ABCL) vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

FLRN, the SPDR Bloomberg Investment Grade Floating Rate ETF, trades at $30.78, showing minimal daily movement with a 0.07% gain. The technical outlook is bearish based on moving averages, though oscillators are neutral. Recent news highlights institutional buying interest amid a higher-for-longer interest rate environment, positioning FLRN as a potential hedge against inflation. The ETF pays consistent dividends, with recent distributions of $0.11 per share.

The outlook for FLRN is cautiously positive, benefiting from its floating-rate structure in a rising rate climate. Key opportunities include inflation protection and steady income, while risks involve interest rate volatility and economic shifts that could impact credit quality. Investor sentiment is mixed, with technical signals leaning bearish but fundamental appeal in current macro conditions.